JO
SABS icon

John Overdeck’s SAB Biotherapeutics SABS Stock Holding History

John Overdeck’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$837K Buy
214,632
+33,447
+18% +$124K ﹤0.01% 3745
2026
Q1 		$694K Buy
+181,185
New +$722K ﹤0.01% 3503
2023
Q3 		– Sell
-2,509
Closed -$20.8K – 3179
2023
Q2 		$20.8K Buy
+2,509
New +$20.6K ﹤0.01% 2902

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

John Overdeck's SABS Position: Q2 2026 in Review

John Overdeck increased its SAB Biotherapeutics (SABS) stake by 18% in Q2 2026, buying an estimated $124K and bringing the position to 214,632 shares worth $837K. The position accounts for ﹤0.01% of the portfolio, ranked #3745.

John Overdeck first reported a position in SABS in Q2 2023 and has held it in 3 quarters since. 86 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • John Overdeck held 214,632 shares of SAB Biotherapeutics worth $837K as of Q2 2026.
  • John Overdeck bought 33,447 SAB Biotherapeutics shares in Q2 2026, an estimated $124K.
  • SAB Biotherapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3745 holding.
  • John Overdeck first reported a position in SAB Biotherapeutics in Q2 2023 and has held it in 3 quarters since.
  • 86 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.